Skip to main content
OpenTrials
Recruiting

NCT Number: NCT01060371

Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCAs and this study will focus on types 1, 2, 3, 6, 7, 8, 10, 27B, and RFC1-ataxia (SCA 1, SCA 2, SCA 3, also known as Machado-Joseph disease, SCA 6, SCA 7, SCA 8, SCA 10, SCA27B, and RFC1-ataxia, also known as CANVAS). The diseases are rare, slowly progressive, cause increasingly severe neurological difficulties, and are variable across and within genotypes. The purpose of this research study is to bring together a group of experts in the field of SCA for the purpose of learning more about the disease.

The research questions are:

1. How do these diseases progress over time? 2. What are the best ways to measure the progression? 3. Do some genes, other than the gene that is abnormal in these diseases, have any effect on the way the disease behaves?

This is a nationwide study and the investigators expect that 1400 patients will participate all over North America. The participants will remain in the study for an indeterminate period of time, for as long as they are willing to participate. Study visits will be done every 12 months.

Within the broader CRC-SCA, there is an Imaging Sub-study aiming to identify magnetic resonance imaging (MRI) markers sensitive to the onset and progression of common SCAs. To accomplish this, participants attend annual visits involving a neurological exam, surveys, a blood draw, and an MRI scan. Participants can attend visits at one of three US locations - Minneapolis, MN; Gainesville, FL; or Dallas, TX and two European locations - Paris, France and Bonn, Germany. Eligible participants must either have SCA1, 2, or 3 or have been a participant of the previous READISCA study (NCT03487367). Gene-positive participants must have a SARA score less than 10; however, there is no SARA limit for participants previously enrolled in READISCA. All participants must be 18 years or older. Gene-negative participants should be 25-65 years old.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Study participants will have 2 teaspoons (10 milliliters) of blood collected during the first/screening visit in order to extract DNA. The sample will be sent to the University of Chicago Genetics Laboratory for the study of genetic factors that modify the course of the disease.

Participants will be asked to return for visits on an annual basis. As part of this study, whole blood samples will be collected from participants at each visit and deposited into a tissue repository called BioSEND (NINDS biomarker repository housed at Indiana University). Sample submissions to the repository may give scientists valuable research material that can help develop new diagnostic tests, new treatments, and new ways to prevent diseases. Scientists will not use participant samples, or material isolated from it, for commercial products or services.

CSF collection is an optional part of this study for SCA participants aged 18 years or older. If a participant declines the CSF collection, the participant will be allowed to continue with participation in the remainder of the study.

Participant samples will not have the participant's name or other personal information linked to it. Samples may be shared with researchers at other institutions. The only information the researchers will keep with the sample is participant age, disease type, the age at onset of disease, and the duration of the disease. The principal investigator at a participant's study site will be the only person who can link the sample to a participant. Participants can have their samples removed from the bank later by written request to their principal investigator.

At each annual visit, study participants will also be asked to complete several assessments that include questionnaires, motor function tests, a cognitive assessment, a neurological exam, and an MRI scan if enrolled in the MRI Sub-study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Affected individuals aged 6 or above with symptoms and/or signs of ataxia with genetic confirmation of SCA 1, 2, 3, 6, 7, 8, 10, 27B, or RFC1-ataxia either in themselves or first degree family member.
  • Any individual aged 18 or above with a definite molecular diagnosis of SCA 1, 2, 3, 6, 7, 8, 10, 27B, or RFC1-ataxia.
  • Former participants of the READISCA (NCT03487367) study.
  • Willingness to participate in the study and ability to give informed consent
  • For MRI Sub-Study only: Previous READISCA enrollees; individuals aged 18 or above with a genetic confirmation of SCA1, 2, or 3 and a SARA score <10 at MRI pre-screening; Healthy control participants without neurological condition.

Exclusion criteria

  • Exclusion of SCA 1, 2, 3, 6, 7, 8, 10, 27B, or RFC1-ataxia by previous DNA testing.
  • A lack of willingness to participate in the study
  • For MRI Sub-study only: Inability to undergo MRI scanning, pregnancy, and other neurological diseases than those of interest.

Treatment and study plan

Genetic Testing

Genetic

About two teaspoons (10 milliliters) of blood will be collected during the first/screening visit to determine SCA type.

Blood collection

Other

Up to 50 milliliters of total blood (whole blood, plasma, serum) may be collected at each visit to measure markers of neurological disease.

Magnetic Resonance Imaging (MRI) Scan

Other

Participants in the sub-study will undergo an MRI scan of head and spine lasting up to 90 minutes at 3 Tesla strength.

Assessments and Questionnaires

Other

Participants will complete various motor function and cognitive assessments and self-report questionnaires.

Cerebrospinal Fluid Collection

Other

(Optional) About 1 1/2 tablespoon (25ml) of CSF collected in adults.

Primary outcomes

  1. Scale for the Assessment and Rating of Ataxia (SARA)

    Time frame: At baseline and then at 12 month intervals for Follow-Up Visit

    The Scale for the Assessment and Rating of Ataxia (SARA) is an 8-item assessment measuring ataxia severity. Total scores are calculated as a sum of item scores and range 0-40, with higher scores indicating greater ataxia severity.

  2. Patient-Reported Outcome Measure of Ataxia (PROM-ataxia)

    Time frame: At baseline and then at 12 month intervals for Follow-Up Visit

    The Patient-Reported Outcome Measure of Ataxia (PROM-ataxia) is a 70-item questionnaire assessing the impact of ataxia on an individual's daily life. Items are rated 0-4, where 0 indicates no difficulty/symptoms and 4 indicates severe difficulty/symptoms. Total scores are a sum of item scores and range 0 to 280 with higher scores indicating greater impact of ataxia symptoms on daily life.

  3. Pons Volume

    Time frame: At baseline and then at a 12 month follow-up Visit

    Pons volume will be measured using MRI and divided by normalized intracranial volume. This measure is a unitless ratio.

  4. Timed 25-Foot Walk (T25-FW)

    Time frame: At baseline and then at 12 month intervals for Follow-Up Visit

    The Timed 25-Foot Walk (T25-FW) measures how fast participants can complete a 25-foot walk in seconds. The final score is an average of 2 trials. A higher scores indicates slower walking and greater gait impairment.

Secondary outcomes

  1. The modified Friedreich Ataxia Rating Scale - Part E (mFARS-E)

    Time frame: At baseline and then at 12 month intervals for Follow-Up Visit

    The modified Friedreich Ataxia Rating Scale - Part E (mFARS-E) is a 7-item comprehensive neurological assessment of upright stability. Item E1 (Sitting) is scored 0-4, Items E2-E5 (Stance) are scored 0-4 based on how many seconds a patient can maintain position without support, and Item E6 (Tandem Walk) is scored 0-3, and Item E7 (Gait) is scored 0-5. Participants may be given up to three attempts (trials) for Items E2-E5, with each attempt recording a score 0-4, and then averaging trial scores for the total Item score. Total score is a sum of item scores on a scale of 0 to 36 points, with higher scores indicating greater impairment and loss of balance.

  2. Friedrich's Ataxia Activities of Daily Living (FA-ADL)

    Time frame: At baseline and then at 12 month intervals for Follow-Up Visit

    The Friedrich's Ataxia Activities of Daily Living (FA-ADL) is a 9-item questionnaire measuring how ataxia affects everyday function. Items are rated 1-5 on an ordinal scale with higher scores indicating greater impairment during daily tasks. Total score is the sum of items scorings, ranging 0-36, with higher scores indicating greater impairment.

  3. Brief Ataxia Rating Scale (BARS)

    Time frame: At baseline and then at 12 month intervals for Follow-Up Visit

    The Brief Ataxia Rating Scale (BARS) is a 5-item assessment measuring cerebellar ataxia severity. Items are scored 0-4. Total scores are a sum of item scores and range 0-20, with higher scores indicating greater ataxia severity.

  4. Cerebellar Cognitive Affective Syndrome (CCAS) Scale

    Time frame: At baseline and then at 12 month intervals for Follow-Up Visit

    The Cerebellar Cognitive Affective Syndrome (CCAS) Scale is a screening instrument to detect the cerebellar cognitive affective syndrome in patients with cerebellar injury. The 12-item scale assesses different cognitive domains. The total possible raw score is 120 points; the Pass/Fail measure provides a maximum fail score of 10 (i.e., 10 failed tests). A fail score of 0 is normal. A participant with a fail score of 1 indicates a Possible CCAS, a fail score of 2 indicates Probable CCAS, and a fail score of 3 or more indicate Definite CCAS.

  5. Nine-Hole Peg Test (9-HPT)

    Time frame: At baseline and then at 12 month intervals for Follow-Up Visit

    The Nine-Hole Peg Test (9-HPT) assesses upper motor dexterity by having participants place and remove 9 pegs, one at a time, as quickly as possible, with one hand at a time. Scores are reported in seconds with higher scores indicated greater upper motor impairment.

  6. EuroQol 5-Dimension Questionnaire (EQ-5D) Index Score

    Time frame: At baseline and then at 12 month intervals for Follow-Up Visit

    The EuroQol 5-Dimension Questionnaire (EQ-5D) is a 6-item questionnaire used to assess a person's health-related quality of life. Items 1-3 are rated 1-3, items 4 and 5 are rated 1-5, and item 6 is a visual analog scale 0-100. Scores on questions 1-5 are converted into a single summary index value between 0 and 1, with lower scores indicating worse health-related quality of life.

  7. Fatigue Severity Scale

    Time frame: At baseline and then at 12 month intervals for Follow-Up Visit

    The Fatigue Severity Scale is a 9-item scale that evaluates the impact of fatigue on a participant's life within the last week. Nine statements are rated on a scale of 1 to 7, where low values indicate strong disagreement with the statement and higher values indicate strong agreement with the statement. An additional item assess global fatigue on a scale 0 to 10, with 0 being the worst and 10 being normal. Total scores are calculated as the sum of ratings from Items 1-9, with higher scores indicating greater fatigue severity.

  8. Fall Questionnaire

    Time frame: At baseline and then at 12 month intervals for Follow-Up Visit

    The Fall Questionnaire is a 5-item scale designed to monitor and capture a participant's number of falls, near-falls, and fall consequences based on the previous three months. Items 1-4 are rated on a scale of 0 to 3 points. Items 1-3 capture frequency of fall, near fall, and worry of falling, where a rating of 0 is Not at All in terms of frequency, up to a rating of 3 fora frequency of at least one time per week (over 13 or more times in 3 months). Item 4 is rated based on severity of injuries, if any, where 0 is Not at all for sustaining injuries, 1 is mild injuries, 2 is moderate injuries, and 3 is severe injuries. The scores from all four questions are summed to give a total score of 0-12 points, where higher scores indicate more severe fall history. Item 5 captures qualitative information on the circumstances of the fall and possible causes.

Study contacts

Contact information is provided by the study sponsor or research team.

Laura P Crespo

CONTACT

[email protected]

763-553-0085

Sponsors and collaborators

Lead sponsor

Lauren Moore

Other

Collaborators

  • Centre hospitalier de l'Université de Montréal (CHUM)
  • Columbia University
  • Emory University
  • Johns Hopkins University
  • Massachusetts General Hospital
  • National Ataxia Foundation
  • Northwestern University
  • The Methodist Hospital Research Institute
  • University of California, Los Angeles
  • University of California, San Francisco
  • University of Chicago
  • University of Florida
  • University of Michigan
  • University of Minnesota
  • University of Pennsylvania
  • University of South Florida
  • University of Texas Southwestern Medical Center
  • University of Washington

Registry information

Official study title

Clinical Research Consortium for the Study of Cerebellar Ataxias (CRC-SCA) for the Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias (SCA)

Important dates

Study start
2010
Primary completion
2030
Study completion
2030
First posted
Feb 2, 2010
Registry last updated
Aug 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.